• The center will provide patients in the Kingdom and the Gulf Cooperation Council countries with advanced treatment services in cardiovascular diseases according to the highest international standards and practices, providing them with world-class care close to them.
• In line with the Kingdom's Vision 2030, the center aims to reduce the need for travel abroad for treatment, develop specialized care within the Kingdom, and enhance the private sector's contribution to healthcare.

Dammam, Saudi Arabia – In a move representing a significant advancement in cardiovascular services across the region, Johns Hopkins Aramco Healthcare (JHAH) announced the opening of its Center of Excellence in Cardiovascular Medicine in Dhahran, Saudi Arabia. This is the second Center of Excellence in the Kingdom, following the success of its Center of Excellence in Oncology, and represents a further step towards establishing a comprehensive, specialized healthcare system throughout the Kingdom.

The new center is based on the model of the renowned American Heart and Vascular Institute, offering comprehensive services based on evidence-based treatment protocols, with excellence centered around the patient and their needs.

With its doors open to patients locally and regionally, the center is responding to critical health needs, as cardiovascular diseases are the leading cause of death in the Kingdom, with the risk of the number of cases expected to rise to more than 479,500 citizens by 2035, more than double the current number, as a result of aging factors, lifestyle-related diseases and nutritional risks.

To meet this growing demand, the center will offer comprehensive care in the fields of cardiology, cardiac surgery, and vascular medicine under a single program. Specialized physicians will manage complex cardiovascular cases and design personalized treatment plans tailored to each patient's needs, ensuring continuity and quality of care. This will be supported by multidisciplinary teams and state-of-the-art technology. The center will strive to achieve optimal outcomes through evidence-based protocols and innovative treatments, in addition to serving as a platform for training medical professionals, conducting research studies, and developing new therapies.

In his statement on this subject, Dr. Russell Hales, President of Centers of Excellence at Johns Hopkins Aramco Healthcare, said: “The new center is more than just a qualitative leap for Johns Hopkins Aramco Healthcare; it will provide patients in the Kingdom and the GCC as a whole with leading treatment solutions. For many, access to specialized cardiac care used to mean traveling abroad or not receiving it at all. Today, our new center aims to change this reality by providing reliable care closer to them, based on the credibility of Johns Hopkins Medicine.”

It is worth mentioning that Dr. Russell Hales is a prominent professor of radiation oncology at Johns Hopkins University in the United States, which confirms the center's commitment to applying the highest standards and best practices, raising the quality of care and ensuring that patients receive exceptional treatment within the Kingdom and the region, as part of the transformation path in the Saudi healthcare sector.

The Center of Excellence in Cardiovascular Medicine at Johns Hopkins Aramco Healthcare offers a coordinated and comprehensive model of cardiac care based on international best practices, combining the scale and integration of services characteristic of official centers of excellence with the global expertise of Johns Hopkins Medicine. This unique collaboration sets a new standard for cardiovascular services in Saudi Arabia and the GCC region, ensuring patients receive advanced, world-class care without needing to travel abroad.

About Johns Hopkins Aramco Healthcare (JHAH) :

The Johns Hopkins Aramco Healthcare (JHAH) , a leading healthcare provider, was established in 2014 as a joint venture between Saudi Aramco and Johns Hopkins Medicine (JHM) . This decade-long collaboration combines Saudi Aramco’s long-standing medical heritage, dating back to the Saudi Aramco Medical Services Organization (SAMSO) since 1945, with JHM ’s global leadership in clinical medical innovation, advanced medical research, and distinguished education.

The center provides world-class, patient-centered healthcare across multiple specialties, including cardiovascular medicine, oncology, urology (including robotic urological surgery), mental health, otolaryngology (ENT), gastroenterology, ophthalmology, and allergy and immunology. Leveraging Aramco’s resources and JHM’s expertise, the center integrates innovative care models such as telemedicine, home hospital services, and AI-enhanced diagnostics to deliver comprehensive, accessible, and personalized care tailored to each patient’s needs. By pushing the boundaries of precision medicine, advancing digital innovation in healthcare, and developing specialized national talent, the center continues to meet the diverse needs of the communities it serves.

For more details, please visit the website: www.jhah.com

-I finish-

#Company Data

Disclaimer regarding the content of press releases
The content of this press release is provided by a third-party provider. We do not assume any responsibility for, nor do we have any control over, such content. This content is provided on an "as is" and "as available" basis and is not edited in any way. Neither we, nor our affiliates, will be liable for the accuracy, endorsement, or completeness of any opinions, views, information, or materials contained in this content.
This press release is provided for informational purposes only; the content does not constitute legal, investment, or tax advice, nor does it offer any opinion on the suitability, value, or profitability of any particular portfolio or investment strategy. Neither we nor our affiliates will be liable for any errors or inaccuracies in the content, or for any actions you take based on that content. You expressly agree and acknowledge full responsibility for your use of the information contained in this press release.
To the extent permitted by applicable law, Refinitiv, its parent company, subsidiaries, affiliates, relevant shareholders, directors, officers, employees, agents, advertisers, content providers, and licensors (collectively, the 'Refinitiv Parties') shall not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages; This includes, but is not limited to, losses of profits, savings, or revenues, whether due to negligence, tort, contract, or other theories of liability, even if the parties to Refinitiv were advised of the possibility of any such damages or losses occurring or actually anticipated them.